- Otamixaban
-
Otamixaban Systematic (IUPAC) name Methyl (2R,3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate Clinical data Pregnancy cat. ? Legal status ? Identifiers CAS number 193153-04-7 ATC code None PubChem CID 5496659 ChemSpider 4593439 UNII S173RED00L ChEMBL CHEMBL46618 Chemical data Formula C25H26N4O4 Mol. mass 446.498 g/mol SMILES eMolecules & PubChem (what is this?) (verify) Otamixaban (INN) is a direct factor Xa inhibitor,[1] currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.
References
- ^ Guertin KR, Choi YM (2007). "The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development". Curr. Med. Chem. 14 (23): 2471–81. doi:10.2174/092986707782023659. PMID 17979700. http://openurl.ingenta.com/content/nlm?genre=article&issn=0929-8673&volume=14&issue=23&spage=2471&aulast=Guertin.
This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it.